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Abstract
Background: Excess cholesterol in bile and in blood is a major risk factor for the respective
development of gallbladder disease and atherosclerosis. This lipid in excess negatively impacts the
functioning of other smooth muscles, including the intestine. Serotonin is an important mediator
of the contractile responses of the small intestine. Drugs targeting the serotonin receptor are used
as prokinetic agents to manage intestinal motor disorders, in particular irritable bowel syndrome.
Thus, tegaserod, acting on 5-HT4 receptor, ideally should obviate detrimental effects of excessive
cholesterol on gastrointestinal smooth muscle. In this study we examined the effect of tegaserod
on cholesterol-induced changes in the contractile responses of intestinal smooth muscle.
Methods: The effects of a high cholesterol (1%) diet on the in vitro contractile responses of jejunal
longitudinal smooth muscle from Richardson ground squirrels to the cholinergic agonist carbachol
were examined in the presence or absence of tetrodrodotoxin (TTX). Two groups of animals, fed
either low (0.03%) or high cholesterol rat chow diet, were further divided into two subgroups and
treated for 28 days with either vehicle or tegaserod.
Results:  The high cholesterol diet increased, by nearly 2-fold, contractions of the jejunal
longitudinal smooth muscle elicited by carbachol. These cholinergic contractions were mediated by
muscarinic receptors since they were blocked by scopolamine, a muscarinic receptor antagonist,
but not by the nicotinic receptor antagonist, hexamethonium. Tegaserod treatment, which did not
affect cholinergic contractions of tissues from low cholesterol fed animals, abrogated the increase
caused by the high cholesterol diet. With low cholesterol diet TTX enhanced carbachol-evoked
contractions, whereas this action potential blocker did not affect the augmented cholinergic
contractions seen with tissues from animals on the high cholesterol diet. Tegaserod-treatment
removed the effects of a high cholesterol diet on neuronal muscarinic receptors, as the potentiating
effect of TTX on carbachol-elicited contractions was maintained in these animals.
Conclusion: A high cholesterol diet causes significant changes to cholinergic neurotransmission in
the enteric nerves of the jejunum. The mechanisms by which these effects of cholesterol are
reversed by tegaserod are unknown, but relate to removal of an inhibitory effect of cholesterol on
enteric nerves.
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Background
In cholesterol gallstone formation, gallbladder smooth
muscle develops reduced contractions, and the resulting
impaired emptying leads to stasis. This dysfunction
retains the cholesterol crystals that have nucleated from
the supersaturated bile; the microcrystals agglomerate and
stone growth follows [1,2]. Patients with gallstones also
exhibit delayed small intestinal [3] and colonic [4] transit,
which results in decreased enterohepatic cycling of bile
salts [5] and so increases deoxycholic acid formation from
cholic acid [6]. The deoxycholic acid and the reduced
enterohepatic cycling adversely influence hepatic bile salt
and cholesterol secretion and contribute to the formation
of bile supersaturated with cholesterol.
A participatory role of the intestine in gallstone formation
has also been established in animal models of gallbladder
disease. The Richardson ground squirrel and the prairie
dog on a high cholesterol diet develop lithogenic bile con-
taining excess cholesterol relative to its solubilizing capac-
ity [7,8]. Smooth muscle function of these animals is
altered negatively: their gallbladders exhibit reduced con-
tractile responses to CCK8 and acetylcholine [8], while
small intestine transit and the cycle period of migrating
myoelectric complexes are prolonged [9,10]. The basis for
these intestinal motility changes is unknown, but might
relate to the excess biliary cholesterol excreted into the
duodenum and/or the hypercholesterolemic state of the
animal model fed a high cholesterol diet.
From a therapeutic perspective, "prokinetic" agents, such
as indoramin, an alpha-adrenergic antagonist, cisapride, a
5-HT4-agonist/5-HT3-antagonist, and erythromycin, a
motilin agonist, promote small and large bowel transit,
and enhance gallbladder emptying and so hinder gall-
stone formation [10,11]. In Richardson ground squirrels,
cisapride reverses the defect in gallbladder contractility,
enhances bile salt secretion and lowers cholesterol satura-
tion [11]. Since cisapride is now known to cause cardiac
rhythm disturbances [12], a new prokinetic agent, tegase-
rod, a partial 5-HT4-agonist [13], which enhances peristal-
sis, was approved for the treatment of patients exhibiting
symptomatic irritable bowel syndrome (IBS) with consti-
pation. IBS generally is associated with an increased risk of
abdominal surgery, including cholecystectomy [14].
Hence, drugs used to treat this condition should not
adversely affect gallbladder function. In a recent human
study, tegaserod did not alter gallbladder contractility or
the diameter of the common bile and hepatic ducts [15].
Nonetheless, the effects of tegaserod on small bowel func-
tion when there is a predisposition to gallstone formation
are not known.
Since serotonin agonists contribute to the contractile
responses of the small intestine [16,17] and are used to
manage intestinal motor disorders [18,19], we postulated
that tegaserod would modify cholesterol-induced changes
in the contractile responses of intestinal smooth muscle.
To test this hypothesis we examined the effects of tegase-
rod on cholinergic-induced contractions of the longitudi-
nal smooth muscle of jejunal and ileal tissues obtained
from Richardson ground squirrels that were maintained
for 28 days on either a low (0.03%) or a high (1%) cho-
lesterol diet.
Methods
Experimental animals
The University of Calgary Animal Care Committee
approved the research protocol, which conforms to the
guidelines of the Canadian Council on Animal Care. 76
Richardson ground squirrels (Spermophilus richardsoni)
were trapped wild near Calgary, Alberta and were given
ivermectin (Merial Canada Inc., Baie d'Urfé, QC, Canada)
shortly after capture to eliminate nematode parasites. The
animals were acclimatized for a minimum period of four
weeks by caging them individually in thermoregulated
rooms on a 12 h/12 h day/night light cycle with free access
to a standard rat chow diet. Most animals adjusted well to
captivity and gained weight, but 4 (7%) of them did not
thrive or gain weight and were excluded from the study.
After acclimatization, the animals were fed, under the
same holding conditions for an additional four weeks,
either a low cholesterol (normal) diet (0.03%, Dyets Inc.,
Bethlehem, PA, USA) or a high cholesterol diet (Dyets
Inc.), comprising an identical chow enriched with 1%
cholesterol by weight. During this diet period the animals
were injected subcutaneously, twice daily, with either
vehicle or 0.1 mg/kg of tegaserod (kindly supplied by
Novartis Pharma, Basel, Switzerland). Tegaserod was dis-
solved in vehicle (100% 1-methyl-2-pyrrolidinone)
immediately before use, and then diluted into 154 mM
NaCl such that the final concentration of 1-methyl-2-pyr-
rolidinone was 2.7%. The vehicle-treated animals received
2.7% 1-methyl-2-pyrrolidinone (Sigma-Aldrich, St. Louis,
MO, USA) in 154 mM NaCl. The animals were randomly
divided into four groups, with 18 in each group and
received the following combination of diet and drug: (1)
vehicle + low cholesterol diet, (2) vehicle + high choles-
terol diet, (3) tegaserod + low cholesterol diet, and (4)
tegaserod + high cholesterol diet. The treatments were
organized so that 2 animals from any one treatment group
were used for experiments 28 days later. Gallbladder and
hepatic bile cholesterol concentration and intestinal con-
tractility were measured with all animals.
Cholesterol concentrations in hepatic and gallbladder bile
For collection of common duct bile animals were fasted
for 14 hours, and then anesthetized and maintained on a
low concentration (1.5 to 2%) isoflurane (Ayerst Labora-
tories, Montreal, QC, Canada). At laparotomy the cysticBMC Gastroenterology 2006, 6:8 http://www.biomedcentral.com/1471-230X/6/8
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duct was exposed and ligated, the gallbladder removed
and the bile collected for subsequent analysis. The com-
mon bile duct was cannulated with a polyethylene cathe-
ter (PE50), and hepatic bile was collected for two one-
hour periods. During this period 154 mM NaC1 was
infused continuously IV at 2.5 mL/h via a femoral venous
cannula for fluid replacement.
Cholesterol was measured using the Liebermann-Bur-
chard reaction (Cholesterol/Cholesteryl Ester Quantita-
tion Kit™ of Biovision; Mountain View, CA, USA).
Intestinal contractility in vitro
At the end of the collection period for hepatic bile the
intestine was removed to evaluate contractile responses of
smooth muscle [9]. Four 2 cm lengths of intestine were
obtained in each animal, two from the proximal jejunum
at a point 5 cm distal to the ligament of Treitz, and two
from the distal ileum at a location 15 cm proximal to the
ileocecal valve. Without occluding the lumen, 5-0 silk
threads were tied to opposite ends of each segment with
one end fixed to the bottom of a 20 mL organ bath, and
the other to an isometric force-displacement transducer
(FT03; Grass Telefactor, West Warwick, RI, USA)). This
montage measured the contractile response of the longi-
tudinal smooth muscle layer. The baths, maintained at a
temperature of 35°C, were filled with a modified Krebs
solution of the following composition (in mM): NaC1
103, KC1 4.7, MgC12 1.13, NaHCO3 25, NaH2PO4 1.15,
CaC12 2.56, D-glucose 2.8, sodium pyruvate 4.9, sodium
fumarate 2.7, and sodium glutamate 4.9: at pH 7.4, con-
tinuously gassed with a mixture of 95% O2 and 5% CO2.
The tissues were stretched to 1 gm of tension, and equili-
brated for 40 min with a change of physiological buffer
every 10 min, and appropriate adjustment of tension.
After equilibration, the longitudinal intestinal segments
underwent cumulative dose-responses (10-8M to 10-4M)
to carbamylcholine chloride (carbachol; Sigma-Aldrich),
performed either in the presence or absence of either 10-
7M tetrodotoxin (TTX; Sigma-Aldrich), or 10-5M hexame-
thonium (Sigma-Aldrich). The TTX permitted evaluation
of smooth muscle contractility in the absence of neural
influences, and hexamethonium, a selective nicotinic
antagonist, was used to determine the contribution of nic-
otinic receptors to the increased tone. With each animal a
jejunal or ileal segment was preincubated with either TTX
or hexamethonium for 10 min, whereas the other
untreated segments served as carbachol controls. Scopo-
lamine was added to the tissues after completion of the
cumulative dose-response for carbachol in all animals
groups. At the end of each experiment, the tissue prepara-
tions were lightly blotted and weighed. The contractile
response for each preparation was calculated as stress
(Newtons/m2), normalized to the cross-sectional area of
the longitudinal smooth muscle layer as previously
described [9].
Data analysis
The results are presented as the mean ± SEM. The statisti-
cal functions used that associated with Excel (Microsoft
Office XP, Redmond, WA, USA). Comparisons between
the different concentrations of carbachol for two groups
were made using the unpaired Student's t-test. With cho-
lesterol measurements one-way analysis of variance was
applied, with the differences between groups identified
using the unpaired Student's t-test. Statistical values reach-
ing probabilities of p < 0.05 were considered significant.
Results
Bile cholesterol
For vehicle-treated animals on a low cholesterol diet the
concentration of cholesterol in gallbladder and hepatic
duct bile were 2.84 ± 0.37 (n = 14) and 0.85 ± 0.14 (n =
12) mM, respectively. Tegaserod treatment of low choles-
terol diet animals did not modify cholesterol concentra-
tions in the gallbladder (2.83 ± 0.38 mM; n = 14) or the
hepatic duct (0.67 ± 0.11 mM; n = 13) relative to vehicle-
treated animals. Feeding the animals a high cholesterol
diet for 28 days significantly increased the bile cholesterol
concentrations to 4.33 ± 0.47 (n = 15) and 1.91 ± 0.30 (n
= 14) mM in the gallbladder and hepatic duct, respec-
tively. Treating animals on the high cholesterol diet with
tegaserod did not modify cholesterol concentration in
gallbladder bile (4.04 ± 0.58 mM; n = 14), but reduced it
in hepatic duct bile (1.29 ± 0.19 mM; n = 13) to concen-
trations significantly lower than that seen in the vehicle-
treated, high cholesterol animals. These concentrations of
hepatic duct bile were higher than those seen with tegase-
rod-treated, low cholesterol animals.
Phasic and tonic contractions of intestinal segments
Relative to control animals neither the high cholesterol
diet nor the tegaserod treatment, alone or in combination,
modified basal and carbachol-induced changes in the
phasic contractions of the jejunal and ileal segments. In
addition, neither TTX nor hexamethonium altered the
phasic contractile activity of the intestinal tissues in any of
the animal groups. However, as discussed in the following
sections tonic contractile responses to cholinergic stimu-
lation with carbachol where significantly altered by the
cholesterol diet and tegaserod treatment, and these altera-
tions were further modified by TTX and hexamethonium.
Cholinergic contractions of jejunal longitudinal smooth 
muscle
Isolated jejunal segments from the ground squirrels on a
low cholesterol diet responded in a dose-dependent man-
ner to carbachol with increasing tonic contractions to a
maximal force of 2.1 ± 0. × 102 Newtons/m2 at 10-4M car-BMC Gastroenterology 2006, 6:8 http://www.biomedcentral.com/1471-230X/6/8
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bachol (Figure 1A). In contrast, animals on the high cho-
lesterol diet receiving the vehicle exhibited significantly
greater responses to concentrations of carbachol of 10-7M
and higher, and showed a maximal response of 3.6 ± 0.3
(× 102) Newtons /m2.
After 4 weeks of tegaserod treatment of animals on a low
cholesterol diet, 10-4M carbachol generated a maximal
force of 1.9 ± 0.2 × 102 Newtons/m2 (Figure 1B), which
was similar to the response in vehicle-treated animals. In
contrast, jejunal tissues from tegaserod-treated animals on
the high cholesterol diet did not exhibit any heightened
contractions to carbachol; the maximal response of 2.3 ±
0.3 × 102 Newtons/m2 was 60% smaller than that seen
with vehicle-treated animals on the high cholesterol diet.
Effect of action potential blockade on carbachol-evoked 
contractions
To determine if the cholinergic contractions of the jejunal
longitudinal smooth muscle had a neural component,
contractions of jejunal smooth muscle were measured
after the addition of TTX, a blocker of action potential
conduction. In the presence of TTX the dose-response rela-
tionships to carbachol on tissues from the vehicle-treated
animals on a low cholesterol diet increased approximately
2-fold to 4.4 ± 0.4 (× 102) Newtons/m2 (Figure 2A). Thus,
the carbachol-produced contractions of jejunal smooth
muscle reflects the net action of two processes; a direct
contractile action on smooth muscle, and a relaxation/
inhibition caused by activation of intramural nerves, a
process abrogated by TTX. Since the nicotinic receptor
antagonist, hexamethonium, did not increase carbachol-
elicited contractions (Figure 3A), the potentiation of the
cholinergic contractions after TTX exposure was inde-
pendent of neuronal nicotinic receptors. Scopolamine, a
muscarininc antagonist, used at a concentration of 10-5M,
totally blocked the contractile actions of carbachol (data
not shown), and also abolished spontaneous contrac-
tions.
Animals on the low cholesterol diet treated with tegase-
rod, like the vehicle-treated controls, exhibited increased
contractile responses to carbachol in the presence of TTX
(Figure 2C). Hexamethonium did not modify carbachol-
elicited contractions (Figure 3B). As before, scopolamine
(10-5M) totally blocked any contractile response to carba-
chol (not shown). Thus, with tegaserod treatment carba-
chol contractions of jejunal smooth muscle from low
cholesterol diet animals also reflects the net action of two
processes; a direct contractile action on smooth muscle
and a relaxant action caused by activation of intramural
nerves.
Ileal contractions elicited by carbachol were not modified
by the high cholesterol diet (Figure 4A), TTX (Figure 4B)
or hexamethonium (not shown), indicating that nerve-
dependent potentiation of smooth muscle contractions to
carbachol occurred exclusively in the jejunum. Conse-
quently, only the contractile responses to the jejunum are
presented.
Interactions between cholinergic contractions, action 
potential blockade and a high cholesterol diet
In contrast to the animals on the low cholesterol diet,
cholinergic contractions of tissues from animals on the
high cholesterol diet were not potentiated after exposure
to TTX (Figure 2B). Since carbachol contractions, in the
presence of TTX, were of a similar magnitude in tissues
Cholesterol diet and cholinergic contractions of the longitu- dinal muscle of the jejunum Figure 1
Cholesterol diet and cholinergic contractions of the 
longitudinal muscle of the jejunum. Effects of choles-
terol diet on cholinergic (carbachol) – elicited contractions 
of the jejunum for ground squirrels on a trace (0.027%; Low) 
vs. enriched (1%; High) cholesterol diet for animals treated 
with either vehicle (A) or tegaserod (B). Cumulative dose-
response curve to carbachol were constructed. * High 
greater than Low (P < 0.05); N = 8–9.
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Action potential blockade and contractions of the longitudinal muscle of the jejunum Figure 2
Action potential blockade and contractions of the longitudinal muscle of the jejunum. Effects of tetrodotoxin 
(TTX) on cholinergic contractions of the jejunum of ground squirrel fed either a low (0.027%; A & C) or a high (1%; B & D) 
cholesterol diet. The animals were treated with either vehicle (A & B) or tegaserod (C & D). The action potential blocker tet-
rodotoxin (TTX; 10-7M) was added to the jejunal tissue segments 10 min before constructing a cumulative dose-response 
curve to the cholinergic agonist, carbachol. * TTX greater than No TTX (P < 0.05). N = 8–9.
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obtained from both low and high cholesterol diet ani-
mals, the high cholesterol diet probably increases carba-
chol-induced contractions by removing a cholinergic
neurally-mediated inhibition of tonic smooth muscle
contractions. This inhibition is muscarinic receptor-medi-
ated since hexamethonium did not alter carbachol-
evoked contractions, even in cholesterol-fed animals (Fig-
ure 3B).
For animals on a high cholesterol diet and treated with
tegaserod a significant potentiation of the carbachol-elic-
ited contractions was seen following exposure to TTX (Fig-
ure 2D). This potentiation is comparable to that seen with
tissues from low cholesterol diet animals receiving either
vehicle or tegaserod. Thus, tegaserod treatment restores a
component of carbachol that was abrogated by the high
cholesterol diet.
Discussion
This study reveals that a high cholesterol diet, fed for 28
days, modifies the properties of cholinergic contractions
of jejunal smooth muscle through modulation of cholin-
ergic receptors located on enteric nerves. This action of the
high cholesterol diet was prevented by treating the ani-
mals with tegaserod.
A high cholesterol diet has diverse effects on cholinergic-
mediated smooth muscle contractions of different tissues.
With few exceptions [20] a high cholesterol diet is
reported to decrease, consequent to gallstone formation
[21], the contractile responses of gallbladder smooth
muscle to acetylcholine receptor activation in human
[21], dog [22] and ground squirrels [8,9]. Few studies
have examined the effects of a high cholesterol diet on
intestinal smooth muscle contractions, but for the ileum
either no effect [[8]; this study Figure 4], or increased con-
tractions [9] have been reported. With the jejunum a high
cholesterol diet increases smooth muscle contractile
responses to cholinergic agonists [9], and the present
study suggests that dietary cholesterol inhibits neuronal
muscarinic receptors in the jejunum, allowing for expres-
sion of enhanced direct muscarininc receptor stimulated-
contractions of smooth muscle. The reasons for differen-
tial responses of jejunal and ileal smooth muscle to
cholinergic stimulation are not known, but differences in
the local luminal concentrations of cholesterol metabo-
lites known to modify cholinergic receptors may be an
underlying cause. Taurocholate, which impairs choliner-
gic contractions of the gallbladder [23,24] is four times
more concentrated in gallbladder bile than in hepatic bile
[25]. The glycine and taurine conjugates of deoxycholic
acid act as cholinergic muscarinic receptor antagonists
[26], and their concentrations are possibly increased in
the hepatic bile of cholesterol-fed animals. The absence of
an effect of the high cholesterol diet on cholinergic
responses in the ileum may reflect reduced concentrations
Antagonism of nicotinic receptors and contractions of the longitudinal muscle of the jejunum Figure 3
Antagonism of nicotinic receptors and contractions of the longitudinal muscle of the jejunum. Absence of an effect 
of the nicotinic receptor antagonist, hexamethonium (10-5M) on cholinergic contractions of the jejunum of vehicle-treated 
ground squirrel fed either a low (0.027%; A) or a high (1%; B) cholesterol diet. Hexamethonium was added to the jejunal tissue 
segments 10 min before constructing a cumulative dose-response curve to the cholinergic agonist, carbachol. N = 5–6.
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of cholinergic modifying bile salts consequent to their
enhanced absorption by the ileum relative to the jejunum
[27].
Cholesterol is an essential membrane component serving
as a cofactor for signalling molecules and as a precursor
for steroid hormones. Cholesterol influences many of the
biophysical properties of membranes, and depending on
the receptor, cholesterol influences the affinity, binding
capacity and signal transduction [28]. When inappropri-
ately regulated or excessive, by altering plasma membrane
structure-function, cholesterol can play a crucial role in
many diseases [28]. Cholesterol's participation in cardio-
vascular disease is well established, and some neurologi-
cal [29], immunological [30,31] and gastrointestinal
disorders have cholesterol-related components. Choles-
terol also has established roles in gallbladder disease
[21,32] and modifies other gastrointestinal functions.
Although acute exposure to cholesterol decreases pressure
in rabbit intestinal loops [33] and reduces nitrergic relax-
ation of the rabbit sphincter of Oddi muscle [34], most
cholesterol-related abnormal events probably result from
prolonged exposure to this lipid, and its associated metab-
olites. In the current study animals were fed a high choles-
terol diet for 28 days as with previous studies [9-11], but
the time course for the modification of cholinergic recep-
tor function by the cholesterol diet is not known, and
acute effects cannot be excluded.
A nervous system-dependent component to cholinergic
agonist contractions of the intestinal tissues from Richard-
son ground squirrels was revealed. Since TTX removed an
inhibitory component of cholinergic contractions of the
jejunum from animals on a low cholesterol diet (Figures
2A and 2C), a part of carbachol-elicited contractions, in
low cholesterol dieted animals, are neuronally mediated.
Given that carbachol is a mixed muscarinic-nicotinic
receptor agonist [35], the neuronal component to cholin-
ergic contractions could be mediated by either nicotinic or
muscarininc receptors on neurons and nerve terminals
[36-41]. Since hexamethonium, unlike TTX, did not mod-
ify carbachol contractions (Figure 1B) the potentiation of
the carbachol-elicited contractions did not involve nico-
tinic receptors, but rather neuronal muscarinic receptors.
This modulation by TTX of carbachol-elicited contrac-
tions was not evident in the ileum (Figure 4B), and thus
either neuronal muscarinic receptors are absent, or possi-
bly obscured, in this intestinal segment by the simultane-
ous activation of inhibitory and stimulatory receptors, or,
as discussed above, the cholesterol metabolites causing
the changes in the jejunum are not present in sufficient
concentrations in the more distal segments of the small
intestine.
In the small intestine 5-HT4 receptors, targets for tegase-
rod action are found exclusively on enteric nerves [43].
The 5-HT4 receptors, localized to cholinergic nerves, are
involved in the contraction of smooth muscle from
canine small and large intestines [43,44] and human large
intestines [43]. Mucosal release of 5-HT with activation of
5-HT4 receptors on sensory neurons that relay via enteric
interneurons to cholinergic motor neurons regulates the
peristaltic reflex [45-48]. The rationale for the therapeutic
Cholinergic contractions of ileal longitudinal smooth muscle  in response to a high cholesterol diet and action potential  blockade Figure 4
Cholinergic contractions of ileal longitudinal smooth 
muscle in response to a high cholesterol diet and 
action potential blockade. (A) Effects of cholesterol diet 
on cholinergic (carbachol) – elicited contractions of the 
ileum for ground squirrels on a trace (0.027%; Low) vs. 
enriched (1%; High) cholesterol diet for animals treated with 
vehicle. (B) Effects of tetrodotoxin (TTX) on cholinergic con-
tractions of the ileum of ground squirrels fed a high (1%) 
cholesterol diet and treated with vehicle. The action poten-
tial blocker tetrodotoxin (TTX; 10-7M) was added to the 
jejunal tissue segments 10 min before constructing a cumula-
tive dose-response curve to the cholinergic agonist, carba-
chol. N = 8–9.
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use of agents acting at 5-HT4 receptors to modulate vis-
ceral hypersensitivity supposes that continuous mucosal
stimuli cause auto-inhibition and desensitization of 5-
HT4 receptors [49], and intramural sensory pathways [50].
We did not investigate this sensory-effecter pathway for
smooth muscle activation, but rather we examined, using
a regimen of drug administration used therapeutically, the
actions of tegaserod on cholinergic receptor activation
with carbachol. This 28 day treatment with tegaserod
removed the potentiating effects of cholesterol diet on
cholinergic contractions of the jejunum (Figure 1B) due to
the masking of enteric nerve dependent-mediated inhibi-
tion of jejunal contractions (Figures 1B and 2D). These
effects of tegaserod may also have contributions from
unexplored variables such as changes in cholesterol
metabolism and contraction-dependent reflex-induced
release of 5-HT from enteric nerves.
Conclusion
Maintaining ground squirrels on a high cholesterol diet
for 4 weeks resulted in the removal of an enteric nervous
system-dependent, muscarinic suppression of cholinergic
contractions of jejunal smooth muscle. This cholesterol-
mediated inhibition of muscarinic neuronal transmission
was prevented by tegaserod, a 5-HT4-partial agonist.
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